Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dulaglutide Renoprotection in Type 2 Diabetic Nephropathy
NCT06182891Completed
- Sponsor
- The Affiliated Hospital of Xuzhou Medical University
- Start
- Oct 2021
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Randomised, open-label trial of dulaglutide biosimilar 14028 injection in diabetic nephropathy (DN) (2 arms), sponsored by The Affiliated Hospital of Xuzhou Medical University. Primary endpoints: Urinary Albumin-to-Creatinine Ratio at 12 months and Biomarkers of Epithelial-Mesenchymal Transition at 12 months. Started Oct 2021; status: completed.
02
Drugs
dulaglutide biosimilar 14028 injection
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT06182891.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06182891.